In a lab near UW Hospital, Megan Jandy grows stem cells from people with Down syndrome — 10 batches of cells, most in three-dimensional clusters, each batch featuring one group with the extra chromosome that causes the disorder and one group without it.
Tiny but mighty is a good way of describing our genome – the collection of our DNA. Although not visible to the naked eye, the human genome holds around 21,000 genes and millions of DNA variants, containing the information needed to maintain an organism throughout its life.
Structural pathologies, such as brain, are present at birth in Down syndrome (trisomy 21), reflecting embryonic origins that are generally associated with smaller organs or reduced growth.
Diversity, equity, and inclusion (DEI) are critically important goals for the Waisman Center and UW Madison.
Xinyu Zhao, PhD, and Anita Bhattacharyya, PhD, will partner on research over the next four years to better understand the molecular underpinnings behind the diversity of FXS symptoms and how that diversity may inform the search for effective therapies.
A new paper published by Anita Bhattacharyya, PhD reveals that the differences in brain structure in individuals with Down syndrome (DS or Trisomy 21) may be due to disrupted signaling pathways that alter brain development to result in the incorrect number or placement of cells in the brain.
While working as a health care administrator in Santa Cruz, California during the 2015 Zika virus outbreak, Jose Martinez realized his background in chemistry and pharmacology could be harnessed to set policies that are grounded in science.
Waisman Center researchers are creating a new approach to study how changes to brain development in the womb result in intellectual disability in people with Down syndrome.
Down syndrome (DS, trisomy 21) is characterized by intellectual impairment at birth and Alzheimer’s disease (AD) pathology in middle age. As individuals with DS age, their cognitive functions decline as they develop AD pathology.
The Biden administration’s loosening of restrictions on the use of fetal tissue in research will allow UW-Madison scientists to continue such studies, which opponents have tried several times to ban in Wisconsin.